1460755518-044edbe0-c117-40c5-bf1c-e592503f802b

1. A compound of structural formula I:
or a pharmaceutically acceptable salt thereof, wherein:
T is N;
U is CR1;
V is CR2;
W is CR4;
X is selected from:
(1) \u2014O\u2014, and
(2) \u2014O\u2014CH2\u2014;

Y is selected from:
(1) C3-l0cycloalkyl,
(2) C3-l0cycloalkenyl,
(3) C2-10cycloheteroalkyl,
(4) C2-10cycloheteroalkenyl,
(5) aryl, and
(6) heteroaryl,

wherein each CH2 is unsubstituted or substituted with 1 or 2 substituents selected from C1-6alkyl, \u2014OH and \u2014NH2,and wherein each alkyl is unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from Rc;
each R1 and R2 is independently selected from:
(1) hydrogen,
(2) halogen,
(3) CN,
(4) CF3,
(5) \u2014C1-6alkyl,
(6) \u2014C2-6alkenyl,
(7) \u2014C2-6alkynyl,
(8) \u2014(CH2)pC3-10cycloalkyl,
(9) \u2014(CH2)pC3-7cycloalkyl-aryl,
(10) \u2014(CH2)pC3-7cycloalkyl-heteroaryl,
(11) \u2014(CH2)pC4-l0cycloalkenyl,
(12) \u2014(CH2)pC4-7cycloalkenyl-aryl,
(13) \u2014(CH2)pC4-7cycloalkenyl-heteroaryl,
(14) \u2014(CH2)pC2-10cycloheteroalkyl,
(15) \u2014(CH2)pC2-10cycloheteroalkenyl,
(16) \u2014(CH2)paryl,
(17) \u2014(CH2)paryl-C1-8alkyl,
(18) \u2014(CH2)paryl-C2-8alkenyl,
(19) \u2014(CH2)paryl-C2-8alkynyl-C1-8alkyl,
(20) \u2014(CH2)paryl-C2-8alkynyl-C3-7cycloalkyl,
(21) \u2014(CH2)paryl-C2-8alkynyl-C3-7cycloalkenyl,
(22) \u2014(CH2)paryl-C2-8alkynyl-C2-10cycloheteroalkyl,
(23) \u2014(CH2)paryl-C2-8alkynyl-C2-10cycloheteroalkenyl,
(24) \u2014(CH2)paryl-C2-8alkynyl-aryl,
(25) \u2014(CH2)paryl-C2-8alkynyl-heteroaryl,
(26) \u2014(CH2)paryl-C3-7cycloalkyl,
(27) \u2014(CH2)paryl-C2-10cycloheteroalkyl,
(28) \u2014(CH2)paryl-C2-10cycloheteroalkenyl,
(29) \u2014(CH2)paryl-aryl,
(30) \u2014(CH2)paryl-heteroaryl,
(31) \u2014(CH2)pheteroaryl,
(32) \u2014C2-6alkenyl-alkyl,
(33) \u2014C2-6alkenyl-aryl,
(34) \u2014C2-6alkenyl-heteroaryl,
(35) \u2014C2-6alkenyl-C3-7cycloalkyl,
(36) \u2014C2-6alkenyl-C3-7cycloalkenyl,
(37) \u2014C2-6alkenyl-C2-7cycloheteroalkyl,
(38) \u2014C2-6alkenyl-C2-7cycloheteroalkenyl,
(39) \u2014C2-6alkynyl-(CH2)1-3\u2014O-aryl,
(40) \u2014C2-6alkynyl-alkyl,
(41) \u2014C2-6alkynyl-aryl,
(42) \u2014C2-6alkynyl-heteroaryl,
(43) \u2014C2-6alkynyl-C3-7cycloalkyl,
(44) \u2014C2-6alkynyl-C3-7cycloalkenyl,
(45) \u2014C2-6alkynyl-C2-7cycloheteroalkyl,
(46) \u2014C2-6alkynyl-C2-7cycloheteroalkenyl, and
(47) \u2014C(O)NH\u2014(CH2)0-3phenyl,

wherein each CH2 is unsubstituted or substituted with 1 or 2 substituents selected from: halogen, CF3 , \u2014OH, \u2014NH2,\u2014C1-6alkyl, \u2014OC1-6alkyl, \u2014NHC1-6alkyl, and \u2014N(C1-6alkyl)2, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, phenyl, aryl and heteroaryl is unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from Ra,
provided that at least one of and only one of R1 and R2 is selected from the group consisting of:
hydrogen, halogen, \u2014CN, \u2014CF3, \u2014C1-6alkyl, \u2014C2-6alkenyl and \u2014C2-6alkynyl;
each R4 is independently selected from:
(1) hydrogen,
(2) halogen,
(3) \u2014C1-6 alkyl,
(4) \u2014C2-6 alkenyl,
(5) \u2014C2-6 alkynyl,
(6) \u2014CN,
(7) \u2014CF3,
(8) \u2014OH,
(9) \u2014OC1-6alkyl,
(10) \u2014NH2,
(11) \u2014NHC1-6alkyl,
(12) \u2014N(C1-6alkyl)2,
(13) \u2014SC1-6alkyl,
(14) \u2014SOC1-6alkyl,
(15) \u2014SO2C1-6alkyl,
(16) \u2014NHSO2C1-6alkyl,
(17) \u2014NHC(O)C1-6alkyl,
(18) \u2014SO2NHC1-6alkyl, and
(19) \u2014C(O)NHC1-6alkyl;

R5is selected from:
(1) hydrogen,
(2) \u2014C1-6alkyl,
(3) \u2014CH2CO2H, and
(4) \u2014CH2CO2C1-6alkyl;

each Ra is independently selected from the group consisting of:
(1) \u2014(CH2)m-halogen,
(2) oxo,
(3) \u2014(CH2)mOH,
(4) \u2014(CH2)mN(Rj)2,
(5) \u2014(CH2)mNO2,
(6) \u2014(CH2)mCN,
(7) \u2014C1-6alkyl,
(8) \u2014(CH2)mCF3,
(9) \u2014(CH2)mOCF3,
(10)\u2014O\u2014(CH2)m\u2014OC1-6alkyl,
(11)\u2014(CH2)mC(O)N(Rj)2,
(12)\u2014(CH2)mC(=N\u2014OH)N(Rj)2,
(13)\u2014(CH2)mOC1-6alkyl,
(14) \u2014(CH2)mO\u2014(CH2)m\u2014C3-7cycloalkyl,
(15) \u2014(CH2)mO\u2014(CH2)m\u2014C2-7cycloheteroalkyl,
(16) \u2014(CH2)mO\u2014(CH2)m-aryl,
(17) \u2014(CH2)mO\u2014(CH2)m-heterolaryl,
(18) \u2014(CH2)mSC1-6alkyl,
(19) \u2014(CH2)mS(O)C1-6alkyl,
(20) \u2014(CH2)mSO2C1-6alkyl,
(21) \u2014(CH2)mSO2C3-7cycloalkyl,
(22) \u2014(CH2)mSO2C2-7cycloheteroalkyl,
(23) \u2014(CH2)mSO2-aryl,
(24) \u2014(CH2)mSO2-heteroaryl,
(25) \u2014(CH2)mSO2NHC1-6alkyl,
(26) \u2014(CH2)mSO2NHC3-7cycloalkyl,
(27) \u2014(CH2)mSO2NHC2-7cycloheteroalkyl,
(28) \u2014(CH2)mSO2NH-aryl,
(29) \u2014(CH2)mSO2NH-heteroaryl,
(30) \u2014(CH2)mNHSO2\u2014C1-6alkyl,
(31) \u2014(CH2)mNHSO2\u2014C3-7cycloalkyl,
(32) \u2014(CH2)mNHSO2\u2014C2-7cycloheteroalkyl,
(33) \u2014(CH2)mNHSO2-aryl,
(34) \u2014(CH2)mNHSO2NH-heteroaryl,
(35) \u2014(CH2)mN(Rj)\u2014C1-6alkyl,
(36) \u2014(CH2)mN(Rj)\u2014C3-7cycloalkyl,
(37) \u2014(CH2)mN(Rj)\u2014C2-7cycloheteroalkyl,
(38) \u2014(CH2)mN(Rj)\u2014C2-7cycloheteroalkenyl,
(39) \u2014(CH2)mN(Rj)-aryl,
(40) \u2014(CH2)mN(Rj)-heteroaryl,
(41) \u2014(CH2)mC(O)Rf,
(42) \u2014(CH2)mC(O)N(Rj)2,
(43) \u2014(CH2)mN(Rj)C(O)N(Rj)2,
(44) \u2014(CH2)mCO2H,
(45) \u2014(CH2)mOCOH,
(46) \u2014(CH2)mCO2Rf,
(47) \u2014(CH2)mOCORf,
(48) \u2014(CH2)mC3-7cycloalkyl,
(49) \u2014(CH2)mC3-7cycloalkenyl,
(50) \u2014(CH2)mC2-6cycloheteroalkyl,
(51) \u2014(CH2)mC2-6cycloheteroalkenyl,
(52) \u2014(CH2)maryl, and
(53) \u2014(CH2)mheteroaryl,

wherein each CH2 is unsubstituted or substituted with 1 or 2 substituents selected from: oxo, \u2014(CH2)l-3OH, \u2014CN, \u2014NH2, \u2014NH(C1-6alkyl), \u2014N(C1-6alkyl)2, \u2014C1-6alkyl (CH3) , OC1-6alkyl, halogen, \u2014CH2F, \u2014CHF2, \u2014CF3, \u2014CO2H, \u2014CO2C1-6alkyl, \u2014C3-7cycloalkyl, phenyl, CH2phenyl, heteroaryl and CH2heteroaryl, and wherein alkyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl and heteroaryl are unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from: oxo, \u2014(CH2)0-5OH, \u2014CN, \u2014NH2, \u2014NH(C1-6alkyl), \u2014N(C1-6alkyl)2, \u2014C1-6alkyl, OC1-6alkyl, halogen, \u2014CH2F, \u2014CHF2, \u2014CF3, \u2014CO2H, \u2014CO2C1-6alkyl, -SO2C1-6 alkyl, \u2014C3-7cycloalkyl, phenyl, CH2phenyl, heteroaryl and CH2heteroaryl;
each Rb is independently selected from:
(1) hydrogen,
(2) \u2014C1-6alkyl,
(3) \u2014C3-6cycloalkyl,
(4) \u2014C3-6cycloalkenyl,
(5) \u2014C2-6cycloheteroalkyl,
(6) \u2014C2-6cycloheteroalkenyl,
(7) aryl,
(8) heteroaryl,
(9) \u2014(CH2)t-halogen,
(10) \u2014(CH2)s\u2014OH,
(11) \u2014NO2,
(12) \u2014NH2,
(13) \u2014NH(C1-6alkyl),
(14) \u2014N(C1-6alkyl)2,
(15) \u2014OC1-6alkyl,
(16) \u2014(CH2)qCO2H,
(17) \u2014(CH2)qCO2C1-6alkyl,
(18) \u2014CF3,
(19) \u2014CN,
(20) \u2014SO2C1-6alkyl, and
(21) \u2014(CH2)sCON(Re)2,

wherein each CH2 is unsubstituted or substituted with 1 or 2 halogens, and wherein each alkyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl and heteroaryl is unsubstituted or substituted with 1, 2 or 3 halogens;
each Rc is independently selected from:
(1) halogen,
(2) oxo,
(3) \u2014(CH2)rOH,
(4) \u2014(CH2)rN(Re)2,
(5) \u2014(CH2)rCN,
(6) \u2014C1-6alkyl,
(7) \u2014CF3,
(8) \u2014C1-6alkyl\u2014OH,
(9) \u2014OCH2OC1-6alkyl,
(10) \u2014(CH2)rOC1-6alkyl,
(11) \u2014OCH2aryl,
(12) \u2014(CH2)rSC1-6alkyl,
(13) \u2014(CH2)rC(O)Rf,
(14) \u2014(CH2)rC(O)N(Re)2,
(15) \u2014(CH2)rCO2H,
(16) \u2014(CH2)rCO2Rf,
(17) \u2014(CH2)rC3-7cycloalkyl,
(18) \u2014(CH2)rC2-6cycloheteroalkyl,
(19) \u2014(CH2)raryl, and
(20) \u2014(CH2)rheteroaryl,

wherein each CH2 is unsubstituted or substituted with 1 or 2 substituents selected from: oxo, \u2014OH, \u2014CN, \u2014N(Rh)2, \u2014C 1-6alkyl, \u2014OC1-6alkyl, halogen, \u2014CH2F, \u2014CHF2, \u2014CF3, \u2014CO2H, \u2014CO2C1-6alkyl, \u2014C3-7cycloalkyl and heteroaryl, and wherein alkyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from: oxo, \u2014OH, \u2014CN, \u2014N(Rh)2, \u2014C 1-6alkyl, \u2014OC 1-6alkyl, halogen, \u2014CH2F, \u2014CHF2, \u2014CF3, \u2014CO2H, \u2014CO2C 1-6alkyl, \u2014C3-7cycloalkyl and heteroaryl;
each Re, Rg and Rh is independently selected from:
(1) hydrogen,
(2) \u2014C1-6alkyl, and
(3) \u2014O\u2014C1-6alkyl,

wherein alkyl is unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from: \u2014OH, oxo, halogen, C1-6alkyl, \u2014OC1-6alkyl, \u2014NH2, \u2014NH(C1-6alkyl), and \u2014N(C1-6alkyl)2;
each Rj is independently selected from:
(1) hydrogen,
(2) C1-6alkyl,
(3) C3-6cycloalkyl,
(4) \u2014C(O)Ri, and
(5) \u2014SO2Ri,

wherein alkyl and cycloalkyl are unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from: \u2014OH, oxo, halogen, C1-6alkyl, \u2014OC1-6alkyl, \u2014NH2, \u2014NH(C1-6alkyl), and \u2014N(C1-6 alkyl)2;
each Rf and Ri is independently selected from:
(1) C1-6alkyl,
(2) C4-7cycloalkyl,
(3) C4-7cycloalkenyl,
(4) C3-7cycloheteroalkyl,
(5) C3-7cycloheteroalkenyl,
(6) aryl, and
(7) heteroaryl,

wherein alkyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl and heteroaryl are unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from: oxo, \u2014OH, \u2014CN, \u2014NH2, \u2014C1-6alkyl, \u2014OC1-6alkyl, halogen, \u2014CH2F, \u2014CHF2, \u2014CF3, \u2014CO2H, \u2014CO2C1-6alkyl, \u2014C3-7cycloalkyl, and heteroaryl;
n is 0, 1, 2, 3 or 4;
m is 0, 1, 2, 3 or 4;
p is 0, 1, 2, or 3;
q is 0, 1, 2, 3 or 4;
r is 0, 1 or 2;
s is 0, 1, 2, 3 or 4; and
t is 0,1,2,3or 4.
2. The compound according to claim 1 wherein:
T is N;
U is CR1;
V is CR2;
W is CR4;
X is selected from:
(1) \u2014O\u2014, and
(2) \u2014O\u2014CH2\u2014;

Y is selected from:
(1) C3-l0cycloalkyl,
(2) C3-l0cycloalkenyl,
(3) C2-10cycloheteroalkyl,
(4) C2-10cycloheteroalkenyl,
(5) aryl, and
(6) heteroaryl,

wherein cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl and heteroaryl are unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from Rb;
Z is selected from:
(1) oxo,
(2) \u2014CF3,
(3) \u2014C1-6alkyl,
(4) \u2014(CH2)t-halogen,
(5) \u2014(CH2)nCO2H,
(6) \u2014(CH2)nOH, and
(7) \u2014(CH2)SO2C1-6alkyl,
wherein each CH2 is unsubstituted or substituted with 1 or 2 substituents selected from C1-6alkyl, \u2014OH and \u2014NH2, and wherein each alkyl is unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from Rc;
each R1 and R2 is independently selected from:
(1) hydrogen,
(2) halogen,
(3) CN,
(4) CF3,
(5) \u2014Cl-6alkyl,
(6) \u2014C2-6alkenyl,
(7) \u2014C2-6alkynyl,
(8) \u2014(CH2)pC3-10cycloalkyl,
(9) \u2014(CH2)pC3-7cycloalkyl-aryl,
(10) \u2014(CH2)pC3-7cycloalkyl-heteroaryl,
(11) \u2014(CH2)pC4-10cycloalkenyl,
(12) \u2014(CH2)pC4-7cycloalkenyl-aryl,
(13) \u2014(CH2)pC4-7cycloalkenyl-heteroaryl,
(14) \u2014(CH2)pC2-10cycloheteroalkyl,
(15) \u2014(CH2)pC2-10cycloheteroalkenyl,
(16) \u2014(CH2)paryl,
(17) \u2014(CH2)paryl\u2014C3-7cycloalkyl,
(18) \u2014(CH2)paryl\u2014C2-7cycloheteroalkyl,
(19) \u2014(CH2)paryl-aryl,
(20) \u2014(CH2)paryl-heteroaryl,
(21) \u2014(CH2)pheteroaryl,
(22) \u2014C2-6alkenyl-alkyl,
(23) \u2014C2-6alkenyl-aryl,
(24) \u2014C2-6alkenyl-heteroaryl,
(25) \u2014C2-6alkenyl\u2014C3-7cycloalkyl,
(26) \u2014C2-6alkenyl\u2014C3-7cycloalkenyl,
(27) \u2014C2-6alkenyl\u2014C2-7cycloheteroalkyl,
(28) \u2014C2-6alkenyl\u2014C2-7cycloheteroalkenyl,
(29) \u2014C2-6alkynyl\u2014(CH2)1-3\u2014O\u2014aryl,
(30) \u2014C2-6alkynyl-alkyl,
(31) \u2014C2-6alkynyl-aryl,
(32) \u2014C2-6alkynyl-heteroaryl,
(33) \u2014C2-6alkynyl\u2014C3-7cycloalkyl,
(34) \u2014C2-6alkynyl\u2014C3-7cycloalkenyl,
(35) \u2014C2-6alkynyl\u2014C2-7cycloheteroalkyl,
(36) \u2014C2-6alkynyl\u2014C2-7cycloheteroalkenyl, and
(37) \u2014C(O)NH\u2014(CH2)0-3phenyl,

wherein each CH2 is unsubstituted or substituted with 1 or 2 substituents selected from: halogen, CF3, \u2014OH, \u2014NH2, \u2014C1-6alkyl, \u2014OC1-6alkyl, \u2014NHC1-6alkyl, and \u2014N(C1-6alkyl)2, wherein each alkyl, alkenyl and alkynyl is unsubstituted or substituted with 1, 2 or 3 substituents selected from: halogen, CF3, \u2014OH, \u2014NH2, \u2014C1-6alkyl, \u2014OC1-6alkyl, \u2014NHC1-6alkyl, and \u2014N(C1-6alkyl)2, and wherein each cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, phenyl, aryl and heteroaryl is unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from Ra, provided that at least one of and only one of R1 and R2 is selected from the group consisting of: hydrogen, halogen, \u2014CN, \u2014CF3, \u2014C1-6alkyl, \u2014C2-6alkenyl and\u2014C2-6alkynyl;
each R4 is independently selected from:
(1) hydrogen,
(2) halogen,
(3) \u2014C1-6 alkyl,
(4) \u2014C2-6 alkenyl,
(5) \u2014C2-6 alkenyl,
(6) \u2014CN,
(7) \u2014CF3,
(8) \u2014OH,
(9) \u2014OC1-6alkyl,
(10) \u2014NH2,
(11) \u2014NHC1-6alkyl,
(12) \u2014N(C1-6alkyl)2,
(13) \u2014SC1-6alkyl,
(14) \u2014SOC1-6alkyl,
(15) \u2014SO2C1-6alkyl,
(16) \u2014NHSO2C1-6alkyl,
(17) \u2014NHC(O)C1-6alkyl,
(18) \u2014SO2NHC1-6alkyl, and
(19) \u2014C(O)NHC1-6alkyl;

R5 is selected from:
(1) hydrogen,
(2) \u2014C1-6alkyl,
(3) \u2014CH2CO2H, and
(4) \u2014CH2CO2C1-6alkyl;

each Ra is independently selected from the group consisting of:
(1) halogen,
(2) oxo,
(3) \u2014(CH2)mOH,
(4) \u2014(CH2)mN(Rj)2,
(5) \u2014(CH2)mNO2,
(6) \u2014(CH2)mCN,
(7) \u2014C1-6alkyl,
(8) \u2014(CH2)mCF3,
(9) \u2014(CH2)mOCF3,
(10) \u2014OCH2OC1-6alkyl,
(11) \u2014(CH2)mC(O)N(Rj)2,
(12) \u2014(CH2)mC(=N\u2014OH)N(Rj)2,
(13) \u2014(CH2)mOC1-6alkyl,
(14) \u2014(CH2)mO\u2014(CH2)m\u2014C3-7cycloalkyl,
(15) \u2014(CH2)mO\u2014(CH2)m\u2014C2-7cycloheteroalkyl,
(16) \u2014(CH2)mO\u2014(CH2)m-aryl,
(17) \u2014(CH2)mO\u2014(CH2)m-heteroaryl,
(18) \u2014(CH2)mSC1-6alkyl,
(19) \u2014(CH2)mS(O)C1-6alkyl,
(20) \u2014(CH2)mSO2C1-6alkyl,
(21) \u2014(CH2)mSO2C3-7cycloalkyl,
(22) \u2014(CH2)mSO2C2-7cycloheteroalkyl,
(23) \u2014(CH2)mSO2-aryl,
(24) \u2014(CH2)mSO2-heteroaryl,
(25) \u2014(CH2)mSO2NHC1-6alkyl,
(26) \u2014(CH2)mSO2NHC3-7cycloalkyl,
(27) \u2014(CH2)mSO2NHC2-7cycloheteroalkyl,
(28) \u2014(CH2)mSO2NH-aryl,
(29) \u2014(CH2)mSO2NH-heteroaryl,
(30) \u2014(CH2)mNHSO2\u2014C1-6a1kyl,
(31) \u2014(CH2)mNHSO2\u2014C3-7cycloalkyl,
(32) \u2014(CH2)mNHSO2\u2014C2-7cycloheteroalkyl,
(33) \u2014(CH2)mNHSO2-aryl,
(34) \u2014(CH2)mNHSO2NH-heteroaryl,
(35) \u2014(CH2)mC(O)Rf,
(36) \u2014(CH2)mC(O)N(Rj)2,
(37) \u2014(CH2)mN(Rj)C(O)N(Rj)2,
(38) \u2014(CH2)mCO2H,
(39) \u2014(CH2)mOCOH,
(40) \u2014(CH2)mCO2Rf,
(41) \u2014(CH2)mOCORf,
(42) \u2014(CH2)mC3-7cycloalkyl,
(43) \u2014(CH2)mC3-7cycloalkenyl,
(44) \u2014(CH2)mC2-6cycloheteroalkyl,
(45) \u2014(CH2)mC2-6cycloheteroalkenyl,
(46) \u2014(CH2)maryl, and
(47) \u2014(CH2)mheteroaryl,

wherein each CH2 is unsubstituted or substituted with 1 or 2 substituents selected from: oxo, \u2014(CH2)0-3 OH, \u2014CN, \u2014NH2, \u2014NH(C1-6alkyl), \u2014N(C1-6alkyl)2, \u2014C1-6alkyl, \u2014OC1-6alkyl, halogen, \u2014CH2F, \u2014CHF2, \u2014CF3, \u2014CO2H, \u2014CO2C1-6alkyl, \u2014C3-7cycloalkyl, phenyl, CH2phenyl, heteroaryl and CH2heteroaryl, and wherein alkyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl and heteroaryl are unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from: oxo, \u2014(CH2)0-3OH, \u2014CN, \u2014NH2, \u2014NH(C1-6alkyl), \u2014N(C1-6alkyl)2, \u2014C1-6alkyl, \u2014OC1-6alkyl, halogen, \u2014CH2F, \u2014CHF2, \u2014CF3, \u2014CO2H, \u2014CO2C1-6alkyl, -SO2C1-6 alkyl, \u2014C3-7cycloalkyl, phenyl, CH2phenyl, heteroaryl and CH2heteroaryl;
each Rb is independently selected from:
(1) hydrogen,
(2) \u2014C1-6alkyl,
(3) \u2014C3-6cycloalkyl,
(4) \u2014C3-6cycloalkenyl,
(5) \u2014C2-6cycloheteroalkyl,
(6) \u2014C2-6cycloheteroalkenyl,
(7) aryl,
(8) heteroaryl,
(9) \u2014(CH2)t-halogen,
(10) \u2014(CH2)s-OH,
(11) \u2014NO2,
(12) \u2014NH2,
(13) \u2014NH(C1-6ablkyl),
(14) \u2014N(C1-6alkyl)2,
(15) \u2014OC1-6alkyl,
(16) \u2014(CH2)qCO2H,
(17) \u2014(CH2)qCO2C1-6alkyl,
(18) \u2014CF3,
(19) \u2014CN,
(20) \u2014SO2C1-6alkyl, and
(21) \u2014(CH2)sCON(Re)2,

wherein each CH2 is unsubstituted or substituted with 1 or 2 substituents selected from: oxo, \u2014OH, \u2014CN, \u2014N(Rh)2, \u2014C 1-6alkyl, \u2014OC1-6alkyl, halogen, \u2014CH2F, \u2014CHF2, \u2014CF3, \u2014CO2H, \u2014CO2C1-6 alkyl, \u2014C3\u20147cycloalkyl and heteroaryl, and wherein alkyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from: oxo, \u2014OH, \u2014CN, \u2014N(Rh)2, \u2014C1-6alkyl, \u2014OC1-6 alkyl, halogen, \u2014CH2F, \u2014CHF2, \u2014CF3, \u2014CO2H, \u2014CO2C1-6 alkyl, \u2014C3-7cycloalkyl and heteroaryl;
each Re, Rg and Rh is independently selected from:
(1) hydrogen,
(2) \u2014C1-6alkyl, and
(3) \u2014O\u2014Cl-6alkyl,

wherein alkyl is unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from: \u2014OH, oxo, halogen, C1-6 alkyl, \u2014OC1-6 alkyl, \u2014NH2, \u2014NH(C1-6 alkyl), and \u2014N(C1-6alkyl)2;
each Rj is independently selected from:
(1) hydrogen,
(2) C1-6alkyl,
(3) C3-6cycloalkyl,
(4) \u2014C(O)Ri, and
(5) \u2014SO2Ri,

wherein alkyl and cycloalkyl are unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from: \u2014OH, oxo, halogen, C1-6alkyl, \u2014OC1-6alkyl, \u2014NH2, \u2014NH(C1-6alkyl), and \u2014N(C1-6 alkyl)2;
each Rf and Ri is independently selected from:
(1) C1-6alkyl,
(2) C4\u20147cycloalkyl,
(3) C4\u20147cycloalkenyl,
(4) C3\u20147cycloheteroalkyl,
(5) C3\u20147cycloheteroalkenyl,
(6) aryl, and
(7) heteroaryl,

wherein alkyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl and heteroaryl are unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from: oxo, \u2014OH, \u2014CN, \u2014NH2, \u2014C1-6alkyl, \u2014OC1-6alkyl, halogen, \u2014CH2F, \u2014CHF2, \u2014CF3, \u2014CO2H, \u2014CO2C1-6alkyl, \u2014C3-7cycloalkyl, and heteroaryl;
n is 0, 1, 2, 3 or 4;
m is 0, 1, 2, 3 or 4;
p is 0, 1, 2, or 3;
q is 0, 1, 2, 3 or 4;
r is 0, 1 or 2;
s is 0, 1, 2, 3 or 4; and
t is 0, 1, 2, 3 or 4,
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 2, wherein X is \u2014O\u2014; or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 2, wherein Y is selected from:
(1) C3-10cycloalkyl,
(2) C2-10cycloheteroalkyl, and
(3) aryl,

wherein cycloalkyl, cycloheteroalkyl and aryl are unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from Rb; or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 4, wherein Y is selected from:
(1) C3-7cycloalkyl,
(2) C2-l0cycloheteroalkyl, and
(3) phenyl,

wherein each cycloalkyl, cycloheteroalkyl and phenyl is unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from Rb; or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 2, wherein Z is selected from:
(1) \u2014(CH2)nCO2H, and
(2) \u2014(CH2)nOH,

wherein each CH2 is unsubstituted or substituted with 1 or 2 substituents selected from C1-6alkyl, \u2014OH and \u2014NH2; or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 1, wherein each R1 and R2 is independently selected from:
(1) halogen,
(2) \u2014C4-10cycloalkenyl,
(3) -phenyl,
(4) -phenyl\u2014C2-8alkynyl\u2014C1-8alkyl,
(5) -phenyl\u2014C2-3alkynyl\u2014C3-7cycloalkyl,
(6) -phenyl\u2014C2-3alkynyl\u2014C2-10cycloheteroalkyl,
(7) -phenyl\u2014C3-7cycloalkyl,
(8) -phenyl\u2014C2-7cycloheteroalkyl,
(9) -phenyl\u2014C2-10cycloheteroalkenyl,
(10) -phenyl-aryl,
(11) -phenyl-heteroaryl,
(12) -heteroaryl, and
(13) \u2014C2-6alkynyl-phenyl,

and wherein each alkyl, alkynyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, phenyl, aryl and heteroaryl is unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from Ra, provided that at least one of and only one of R1 and R2 is selected from halogen; or a pharmaceutically acceptable salt thereof.
8. The compound according to claim 7, wherein R1 is independently selected from:
(1) \u2014C4-10ocycloalkenyl,
(2) -phenyl,
(3) -phenyl\u2014C2alkynylC1-5alkyl,
(4) -phenyl\u2014C2-3alkynyl- C3-7cycloalkyl,
(5) -phenyl\u2014C2-3alkynyl\u2014C2-10cycloheteroalkyl,
(6) -phenyl\u2014C3-7cycloalkyl,
(7) -phenyl\u2014C2-7cycloheteroalkyl,
(8) -phenyl\u2014C2-10cycloheteroalkenyl,
(9) -phenyl-phenyl,
(10) -phenyl-heteroaryl,
(11) -heteroaryl, and
(12) \u2014C2-6alkynyl-phenyl,

wherein each alkyl, alkynyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, phenyl and heteroaryl is unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from Ra; and
R2 is selected from halogen;
or a pharmaceutically acceptable salt thereof.
9. The compound according to claim 8, wherein each R1 is independently selected from:
(1) -phenyl\u2014C2-7cycloheteroalkyl,
(2) -phenyl\u2014C2-10cycloheteroalkenyl,
(3) -phenyl-phenyl, and
(4) -phenyl-heteroaryl,

wherein each cycloheteroalkyl, cycloheteroalkenyl, heteroaryl and phenyl is unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from Ra; and R2 is halogen;
or a pharmaceutically acceptable salt thereof.
10. The compound according to claim 2, wherein each R1 and R2 is independently selected from:
(1) halogen,
(2) \u2014C4-10cycloalkenyl,
(3) -phenyl,
(4) -phenyl\u2014C3-7cycloalkyl,
(5) -phenyl\u2014C2-7cycloheteroalkyl,
(6) -phenyl-aryl,
(7) -phenyl-heteroaryl,
(8) -heteroaryl, and
(9) \u2014C2-6alkynyl-phenyl,

wherein each alkynyl is unsubstituted or substituted with 1, 2 or 3 substituents selected from: halogen, CF3, \u2014OH, \u2014NH2, \u2014C1-6alkyl, \u2014OC1-6alkyl, \u2014NHC1-6alkyl, and \u2014N(C1-6alkyl)2, and wherein each cycloalkyl, cycloalkenyl, cycloheteroalkyl, phenyl, aryl and heteroaryl is unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from Ra, provided that at least one of and only one of R1 and R2 is selected from halogen; or a pharmaceutically acceptable salt thereof.
11. The compound according to claim 10, wherein R1 is independently selected from:
(1) \u2014C4-10ocycloalkenyl,
(2) -phenyl,
(3) -phenyl\u2014C3-7cycloalkyl,
(4) -phenyl\u2014C2-7cycloheteroalkyl,
(5) -phenyl-phenyl,
(6) -phenyl-heteroaryl,
(7) -heteroaryl, and
(8) \u2014C2\u20146alkynyl-phenyl,

wherein each alkynyl is unsubstituted or substituted with 1, 2 or 3 substituents selected from: halogen, CF3, \u2014OH, \u2014NH2, \u2014C1-6alkyl, \u2014OC1-6alkyl, \u2014NHC1-6alkyl, and \u2014N(C1-6alkyl)2, and wherein each cycloalkyl, cycloalkenyl, cycloheteroalkyl, phenyl and heteroaryl is unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from Ra; and
R2 is selected from: halogen;
or a pharmaceutically acceptable salt thereof.
12. The compound according to claim 11, wherein each R1 is independently selected from:
(1) -phenyl\u2014C2-7cycloheteroalkyl, and
(2) -phenyl-phenyl,

wherein each cycloheteroalkyl and phenyl is unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from Ra, and
R2 is selected from halogen;
or a pharmaceutically acceptable salt thereof.
13. The compound according to claim 2, wherein R4 is hydrogen or absent; and R5 is hydrogen; or a pharmaceutically acceptable salt thereof.
14. The compound according to claim 1 wherein:
T is N;
U is \u2014CR1\u2014;
V is \u2014CR2\u2014;
W is \u2014CR4\u2014;
X is selected from:
(1) \u2014O\u2014, and
(2) \u2014O\u2014CH2\u2014;

Y is selected from:
(1) \u2014C3-10ycloalkyl,
(2) \u2014C2-10cycloheteroalkyl, and
(3) -phenyl,

wherein cycloalkyl, cycloheteroalkyl and phenyl are unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from Rb;
Z is selected from:
(1) oxo,
(2) \u2014CF3,
(3) \u2014C1-6alkyl,
(4) \u2014(CH2)t-halogen,
(5) \u2014(CH2)nCO2H,
(6) \u2014(CH2)nOH, and
(7) \u2014(CH2)nSO2C1-6alkyl,

wherein each alkyl, alkynyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, phenyl and heteroaryl is unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from Ra;
R2 is selected from halogen;
R4 is hydrogen; and
R5 is hydrogen;
or a pharmaceutically acceptable salt thereof.
15. The compound according to claim 2 wherein:
T is N;
U is \u2014CR1\u2014;
V is \u2014CR2\u2014;
W is \u2014CR4\u2014;
X is selected from:
(1) \u2014O\u2014, and
(2) \u2014O\u2014CH2\u2014;

Y is selected from:
(1) C3-10cycloalkyl,
(2) C2-10cycloheteroalkyl, and
(3) phenyl,

wherein cycloalkyl, cycloheteroalkyl and phenyl are unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from Rb;
Z is selected from:
(1) oxo,
(2) CF3,
(3) \u2014C1-6alkyl,
(4) \u2014(CH2)t-halogen,
(5) \u2014(CH2)nCO2H,
(6) \u2014(CH2)nOH, and
(7) \u2014(CH2)nSO2C1-6alkyl,

wherein each alkynyl is unsubstituted or substituted with 1, 2 or 3 substituents selected from:
halogen, CF3, \u2014OH, \u2014NH2, \u2014C1-6alkyl, \u2014OC1-6alkyl, \u2014NHC1-6alkyl, and \u2014N(C1-6alkyl)2, and wherein each cycloalkyl, cycloalkenyl, cycloheteroalkyl, phenyl and heteroaryl is unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from Ra;
R2 is selected from halogen;
R4 is hydrogen; and
R5 is hydrogen;
or a pharmaceutically acceptable salt thereof.
16. The compound according to claim 2 wherein:
T is N;
U is \u2014CR1\u2014;
V is \u2014CR2\u2014;
W is \u2014CR4\u2014;
X is \u2014O\u2014;
Y is selected from:
(1) C3-7cycloalkyl,
(2) C2-10cycloheteroalkyl, and
(3) phenyl,

wherein each cycloalkyl, cycloheteroalkyl and phenyl is unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from Rb;
Z is selected from:
(1) \u2014(CH2)nCO2H, and
(2) \u2014(CH2)nOH,

wherein each CH2 is unsubstituted or substituted with 1 or 2 substituents selected from C1-6alkyl and \u2014OH;
R1is selected from:
(1) -phenyl\u2014C2-7cycloheteroalkyl, and
(2) -phenyl-phenyl,

wherein each cycloheteroalkyl and phenyl is unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from Ra;
R2 is selected from halogen;
R4 is hydrogen; and
R5 is hydrogen;
or a pharmaceutically acceptable salt thereof.
17. The compound according to claim 16, selected from:
or a pharmaceutically acceptable salt thereof.
18. The compound according to claim 1 wherein:
T is N;
U is\u2014CR1\u2014;
V is\u2014CR2\u2014;
W is\u2014CR4\u2014;
X is\u2014O\u2014;
Y is selected from C2-10cycloheteroalkyl, wherein each cycloheteroalkyl is unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from Rb;
Z is selected from: \u2014(CH2)n OH;
R1 is independently selected from:
(1) -phenyl\u2014C2-10 cycloheteroalkenyl,
(2) -biphenyl, and
(3) -phenyl-heteroaryl,

wherein each cycloheteroalkenyl, phenyl, biphenyl and heteroaryl is unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from Ra;
R2 is selected from halogen;
R4 is hydrogen; and
R5 is hydrogen;
or a pharmaceutically acceptable salt thereof.
19. The compound according to claim 18, selected from:
or a pharmaceutically acceptable salt thereof.
20. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
21. A composition comprising a compound according to claim 1 and a compound selected from simvastatin, ezetimibe, taranabant and sitagliptin; and a pharmaceutically acceptable carrier.
22. A method of treating a disorder, condition or disease responsive to the activation of AMP-activated protein kinase in a patient in need thereof comprising administration of a therapeutically effective amount of a compound according to claim 1, wherein the disorder, condition, or disease is selected from the group consisting of:
Type 2 diabetes, hyperglycemia, Metabolic Syndrome, obesity, hypercholesterolemia, hypertension, and cancer.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A machine readable medium that stores instructions which when performed by a wireless device, cause the wireless device to perform operations for configuring a full duplex communication, the operations comprising:
determine an echo cancellation parameter;
send the echo cancellation parameter to a controlling wireless device;
receive a full duplex communication parameter, the full duplex communication parameter determined by the controlling wireless device based upon the echo cancellation parameter; and
responsive to receiving the full duplex communication parameter, simultaneously transmitting packets to and receiving packets from the controlling wireless device using the full duplex communication parameter on the same wireless channel.
2. The machine-readable medium of claim 1, wherein the wireless device is not capable of cancelling out interference from transmissions at maximum power to a level at or below a receiver of the wireless device’s noise floor, and wherein the operations of calculating the full duplex communication parameter comprise calculating the full duplex communication parameter to allow echo cancellation circuitry of the wireless device to cancel a transmission made by the wireless device.
3. The machine-readable medium of claim 1, wherein the echo cancellation parameter is sent in a Medium Access Control (MAC) management message and the full duplex communication parameter is received in a MAC management message.
4. The machine-readable medium of claim 1, wherein the echo cancellation parameter is one of: an amount of echo cancellation the wireless device is capable of, a receiver noise figure, a maximum modulation and coding scheme (MCS), a measurement of the wireless medium, a transmission power, and a full-duplex period duration.
5. The machine-readable medium of claim 1, wherein the full duplex communication parameter is a modulation and coding scheme (MCS).
6. The machine-readable medium of claim 1, wherein the wireless device and the controlling wireless device operate according to one of an 802.11 family of standards.
7. The machine-readable medium of claim 1, wherein the wireless device includes a first and a second antenna, and wherein the operations of simultaneously transmitting packets to and receiving packets from the controlling wireless device comprises using the first antenna for receiving the packets and the second antenna for transmitting the packets to the controlling wireless device.
8. A machine readable medium that stores instructions which when performed by a wireless device, cause the wireless device to perform operations for configuring a full duplex communication, the operations comprising:
determine a first echo cancellation parameter specific to the wireless device;
receive a second echo cancellation parameter from a controlled wireless device;
calculate a full duplex communication parameter, the full duplex communication parameter determined based upon the first and second echo cancellation parameters;
send the full duplex communication parameter to the controlled wireless device; and
responsive to receiving the full duplex communication parameter, simultaneously transmitting packets to and receiving packets from the controlled wireless device using the full duplex communication parameter on the same wireless channel.
9. The machine readable medium of claim 8, wherein the wireless device is not capable of cancelling out interference from transmissions at maximum power to a level at or below a receiver of the wireless device’s noise floor and wherein the operations of calculating the full duplex communication parameter comprise operations for calculating the full duplex communication parameter to allow echo cancellation circuitry of the wireless device to cancel a transmission made by the wireless device and to allow echo cancellation circuitry of the controlled wireless device to cancel a transmission made by the controlled wireless device.
10. The machine readable medium of claim 9, wherein the full duplex communication parameter is a modulation and coding scheme (MCS) and wherein the operations of calculating the MCS comprise calculating the MCS so as to prioritize a connection throughput between the wireless device and the controlled wireless device over a connection latency between the wireless device and the controlled wireless device.
11. The machine readable medium of claim 9, wherein the full duplex communication parameter is a modulation and coding scheme (MCS) and wherein the operations of calculating the MCS comprise calculating the MCS so as to prioritize a connection latency between the wireless device and the controlled wireless device over a connection throughput between the wireless device and the controlled wireless device.
12. The machine readable medium of claim 8, wherein the second echo cancellation parameter is received in a Medium Access Control (MAC) management message and the full duplex communication parameter is sent in a MAC management message.
13. The machine readable medium of claim 8, wherein the echo cancellation parameter is one of: an amount of echo cancellation the wireless device is capable of, a receiver noise figure, a maximum modulation and coding scheme (MCS), a measurement of the wireless medium, a transmission power, and a full-duplex period duration.
14. The machine readable medium of claim 1, wherein the full duplex communication parameter is a modulation and coding scheme (MCS).
15. A wireless device comprising:
a memory and one or more processors configured to include:
a Medium Access Control (MAC) layer module configured to:
determine an echo cancellation parameter;
send the echo cancellation parameter to a controlling wireless device;
receive a full duplex communication parameter, the full duplex communication parameter determined by the controlling wireless device based upon the echo cancellation parameter; and
responsive to receiving the full duplex communication parameter, cause a physical layer module to simultaneously transmit packets to and receive packets from the controlling wireless device using the full duplex communication parameter on the same wireless channel.
16. The wireless device of claim 15, wherein the wireless device is not capable of cancelling out interference from transmissions at maximum power to a level at or below a receiver of the wireless device’s noise floor and wherein the full duplex communication parameter is calculated to allow echo cancellation circuitry of the wireless device to cancel a transmission made by the wireless device.
17. The wireless device of claim 15, wherein the echo cancellation parameter is sent in a Medium Access Control (MAC) management message and the full duplex communication parameter is received in a MAC management message.
18. The wireless device of claim 15, wherein the echo cancellation parameter is one of: an amount of echo cancellation the wireless device is capable of, a receiver noise figure, a maximum modulation and coding scheme (MCS), a measurement of the wireless medium, a transmission power, and a full-duplex period duration.
19. The wireless device of claim 15, wherein the wireless device includes a first antenna and wherein the physical layer is configured to simultaneously transmit packets to and receive packets from the controlling wireless device using the first antenna to both receive the packets and transmit the packets.
20. The wireless device of claim 15, wherein the MAC layer module is configured to send a block acknowledgment acknowledging a plurality of received packets.
21. The wireless device of claim 15, wherein the MAC layer module is configured to:
receive a packet that requires an immediate response and in response:
wait until a current packet is finished transmission;
wait a predetermined amount of time; and
cause an acknowledgment to the packet that requires an immediate response to be transmitted.
22. A wireless device comprising:
a memory and one or more processors configured to include:
a Medium Access Control (MAC) layer module configured to:
determine a first echo cancellation parameter specific to the wireless device;
receive a second echo cancellation parameter from a controlled wireless device;
calculate a full duplex communication parameter, the full duplex communication
parameter determined based upon the first and second echo cancellation parameters;
send the full duplex communication parameter to the controlled wireless device; and
responsive to receiving the full duplex communication parameter, cause a physical layer module to simultaneously transmit packets to and receive packets from the controlled wireless device using the full duplex communication parameter on the same wireless channel.
23. The wireless device of claim 22, wherein the wireless device is not capable of cancelling out interference from transmissions at maximum power to a level at or below a receiver of the wireless device’s noise floor, and wherein the MAC layer is configured to calculate the full duplex communication parameter to allow echo cancellation circuitry of the wireless device to cancel a transmission made by the wireless device and to allow echo cancellation circuitry of the controlled wireless device to cancel a transmission made by the controlled wireless device.
24. The wireless device of claim 23, wherein the MAC layer is configured to calculate the MCS so as to prioritize a connection throughput between the wireless device and the controlled wireless device over a connection latency between the wireless device and the controlled wireless device.
25. The wireless device of claim 23, wherein the MAC layer is configured to calculate the MCS so as to prioritize a connection latency between the wireless device and the controlled wireless device over a connection throughput between the wireless device and the controlled wireless device.
26. The wireless device of claim 22, comprising an antenna coupled to the physical layer.